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ABSTRACT 
 
Objective. To perform a cost-effectiveness analysis (CEA) between a standard 
antiemetic regimen -chlorpromazine + dexamethasone (CPM-DEX)- and a 5-HT3 
receptor antagonist -tropisetron (TROP)- in the control of acute emesis induced by 
highly emetogenic chemotherapy in children, considering two analytic perspectives: 
hospital and patients. 
 
Methods. The CEA was performed by constructing a decision tree, for both analytic 
perspectives, of the possible outcomes of treatment with TROP (single 0.2 mg/kg i.v.) 
or CPM (5-15 mg i.v. infusion for 3 doses) plus DEX (2 mg/m2 i.v. bolus i.v. x 2). The 
patients were stratified by age in two groups (2-12 and 13-17). To estimate the 
probability of each endpoint at the decision tree we have taken as a base a trial 
developed in the Department of Pediatrics. Direct medical cost of primary therapy, 
failure, complications and side effects were included in the cost calculations. 
 
Results. From patients’ analytic perspective, TROP was more cost-effective than CPM-
DEX for both groups of patients. Discrepancy between both analytic perspectives in 13-
17 year-old patient’s group was resolved in favour of the option chosen from the 
patients’ analytic perspective (TROP). Sensitivity analysis showed the reliability of the 
results. 
 
Conclusions. 1. TROP was more cost-effective than CPMDEX. 2. Taking into account 
the patients’ analytic perspective is essential when we compare antiemetics 
pharmacoeconomically. 3. It seems necessary to increase the effectiveness of TROP in 
pediatric patients receiving highly emetogenic chemotherapy 
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INTRODUCTION 
 
Of the standard antiemetic regimens (ARs), chlorpromazine (alone or in combination) 
has been the most widely used in infantile oncology because of its favourable 
safety/efficacy relationship [1]. The growing complexity of chemotherapy treatments 
and the appearance of new antiemetics (5-HT3 receptor antagonists) has resulted in a 
gradual increase in the number and quality of clinical trials of antiemetics in children [2-
9]. Parallel to this, the need to develop pharmacoeconomic evaluations as a complement 
to these safety and efficacy studies has been seen. 
  
The aim of this study is to carry out a cost-effectiveness analysis (CEA) between a 
standard antiemetic regimen (AR)-chlorpromazine + dexamethasone (CPM-DEX)- and 
a 5-HT3 receptor antagonist -tropisetron (TROP)- in the control of acute emesis induced 
by highly emetogenic chemotherapy in pediatric patients with cancer, considering two 
analytic perspectives: hospital and patients. 
 
A pharmacoeconomic comparison was made between one alternative of proven 
effective [10-11] and low cost -CPM-DEX- and an option which is apparently more 
efficient clinically [5 6 9] but with higher costs -TROP-. The inclusion of a nil 
alternative in the study was not considered because of the high incidence of acute 
chemotherapy-induced emesis in pediatric patients who do not receive antiemetic 
prophylaxis prior to the administration of highly emetogenic chemotherapy [12]. 
 
 
 
METHODS 
 
The CEA was performed by constructing a decision tree for both analytic perspectives 
(Figures 1 and 2) of the possible outcomes of treatment with TROP (single 0.2 mg/kg; 
30 minutes; i.v. infusion prior to chemotherapy) or CPM (5-15 mg; 120 minutes; i.v. 
infusion prior to chemotherapy and 2 doses repeated every 6 hours) plus DEX (2 
mg/m2; bolus i.v. prior to chemotherapy and repeated 12 hours later). 
 
The therapeutic options were evaluated in terms of effectiveness. The results of 
effectiveness were evaluated in natural units related to the final health outcome. 
Therefore the parameter/unit of effectiveness (common health outcome) was established 
taking into account the antiemetic response and the tolerability of both ARs. 
 
From the hospital’s analytic perspective the parameter/unit of effectiveness was 
established as follows: “day of chemotherapy with total control of acute emesis without 
probable or definitive collateral adverse effects produced by AR or with probable or 
definitive adverse effects induced by AR but not requiring treatment”. 
 
From the patients’ analytic perspective the parameter/unit of effectiveness was 
established as follows: “chemotherapy cycle in which the evaluation of antiemetic 
response and AR tolerability on the part of the patient, or his or her caregiver, is 
satisfactory”. These are therefore positive end-points of the decision trees: T2, T3, CD2 
and CD3 from the hospital’s analytic perspective and Ta, Tb, CDa and CDb from a 
patients’ analytic perspective. 
 
PROBABILITY CALCULATIONS 
 
To estimate the probability of each end-point at the decision trees we have introduced 
the appropriate changes in a randomized, double blind, serially crossed, prospective 
efficacy and safety study of TROP vs. CPM-DEX to adapt it to the associated economic 
evaluation and to the real clinical situation. The study was carried out by the 
Department of Pediatric Oncology of the University Hospital of Navarra (UHN) in 
collaboration with the Pharmacy Service of the aforementioned hospital. 
 
Data of the antiemetic response and the tolerability of both AR in 30 patients (16 male 
and 14 female) aged between 2 and 17 years (mean age 11.5 years) was collected in the 
period between April 1995 and April 1996. Prior to the study the informed consent of 
all patients (or their legal representative) was obtained as was the approval of the ethics 
committee of the hospital. 
 
All the patients had been diagnosed as having a solid malignant tumour. The patients 
received highly emetogenic chemotherapy: 
 Combinations of iphosphamide ≥ 1 g/m2 with another highly emetogenic 
cytotoxic (cisplatin ≥ 30 mg/m2 or dactinomycin ≥ 0,3 mg/m2 or carboplatin ≥ 
150 mg/m2) ± a moderately or slightly emetogenic cytotoxic. 
 Combination of 1 highly emetogenic cytotoxic (iphosphamide ≥ 1 g/m2, 
methotrexate ≥ 1 g/m2, dacarbazine ≥ 100 mg/m2, cisplatin ≥ 30 mg/m2, 
doxorubicin ≥ 45 mg/m2, dactinomycin ≥ 0,3 mg/m2, carboplatin ≥ 150 mg/m2, 
cyclophosphamide > 1 g/m2) ± a moderately or slightly emetogenic cytotoxic. 
 
From the hospital’s analytic perspective, data were collected over 221 days of highly 
emetogenic chemotherapy, corresponding to a total of 87 cycles. For 110 of these days 
the patients received CPM-DEX as AR and TROP for the other 111 days. The number 
of emetic episodes experienced in the 24 hour period following the start of the 
administration of chemotherapy, as well as the verbal evaluation of nausea in this same 
interval of time were recorded by the patient or caregiver. The definitive or probably 
attributable adverse effects of the ARs and/or the complications due to poor emetic 
control were recorded by the researcher. Information regarding adverse effects 
treatment and a possible increased hospitalisation time of the patient (as a consequence 
of adverse effects or as a consequence of the poor emetic control) was taken from a 
review of the clinical history. From the patients’ analytic perspective data was collected 
from a total of 87 chemotherapy cycles. The patients received CPM-DEX as AR in 43 
of the cycles and TROP in the remaining 44. The antiemetic response and tolerability to 
the adverse effects and/or complications were evaluated by the patient or carer once the 
cycle had concluded. 
 
 
 
COST ESTIMATES 
 
Direct medical costs of primary therapy, failure, complications and side effects were 
included in the cost calculations of each end-point at the decision tree. Data of direct 
medical cost were collected from over 221 of highly emetogenic chemotherapy 
(Hospital’s analytic perspective), corresponding to 87 cycles (patients’analytic 
perspective). However neither direct nonmedical costs or indirect costs were considered. 
Intangible costs were not studied implicitly although they were studied explicitly when 
evaluating the antiemetic response and the tolerability of the ARs from the patients’ 
analytic perspective. We have considered that the percentage payment made by the 
patient is in the 100% range (no capitation, no copayment, no coinsurance). 
 
The quantification and the economic valuation of each identified resource are shown in 
Annex 1 from the hospital’s analytic perspective and in Annex 2 from a patients’ 
analytic perspective. The specific units of quantification of each identified potential cost 
and the sources of information about these units are shown in Table 1. The 
corresponding monetary value assigned to each identified potential cost was based on 
the following sources of information: Biochemical Laboratory, UHN Personnel 
Department, UHN Analytical Accounting, UHN Internal Administration and UHN 
Pharmacy Service. 
 
 
 
SUBGROUPS OF ANALYSIS 
 
The age of the patients defined the limits of the two subgroups on this CEA: patients 2-
12 years of age (n=16) and patients 13-17 years of age (n=14). 
 
 
 
UPDATING COSTS AND EFFECTS 
 
It was not necessary to discount either the costs or effects with regard to the time at 
which the pharmacoeconomic evaluation was carried out, given that the temporal 
horizon was less than one year. Costs and effects were produced in the same time 
horizon. 
 
 
 
ANALYSIS OF THE RELATION COSTS-EFFECTS 
 
Cost-effectiveness ratio (CEr) for both ARs, incremental cost (IC), incremental 
effectiveness (IE) and incremental cost-effectiveness (ICE) were established from the 
two analytic perspectives in both age groups. 
 
The values of IE (difference between the probability in percentage of obtaining as a 
result of treatment with TROP one unit of effectiveness and the probability of obtaining 
the same result with CPM-DEX) and their relationship with IC (cost of treating 100 
days or 100 cycles of chemotherapy with TROP minus the cost of treating the same 
number of days or cycles of chemotherapy with CPM-DEX) have given rise to the 
following two situations: 
1. The values for IE are lower than -4,9%. In this case CPM-DEX is more effective 
and cheaper than TROP and therefore considered the most cost-effective alternative. 
2. IE is higher than + 4,9%. In this case TROP is more effective than CPM-DEX, 
but has higher costs. Thereby in order to determine the more cost-effective AR it is 
necessary to establish hospital’s and patients’ willingness to pay per extra effectiveness 
unit. 
It was assumed that the hospital would be willing to pay 50% more than CPM-DEX 
cost-effectiveness ratio (CEr CD) per extra effectiveness unit; TROP would therefore be 
chosen as the most cost-effective option if: 
 
 
 
Patients’ willingness to pay per extra effectiveness unit was determined by a function 
based on a theoretical model. The function correlates the percentage increase -which 
incremental effectiveness supposes for the percentage CPM-DEX effectiveness (X)- 
with the higher percentage over CEr CD which the patients or relatives are willing to 
pay for such an increase in effectiveness (Y). 
 
 
 
PIF being a proportional incremental factor which in the base case has the value: 
 
 
 
The graph of the function of the theoretical model (figure 3) divides the first quadrant of 
the plane into two areas: A and B. From the patients’ analytic perspective TROP is 
more cost-effective than the alternative CPM-DEX if the point: 
  
 
 
 is found in area A of the graph in Figure 3. 
 
 
  
6. SENSITIVITY ANALYSIS 
 
From the Hospital’s analytic perspective we studied the impact on the results of the 
pharmacoeconomic evaluation of variations in the following key variables: Tropisetron 
acquisition cost, Human Resources in AR CPM-DEX and Hospital willingness to pay 
per extra effectiveness unit (Table 2a). 
 
From patients’ analytic perspective we studied the impact on the results of the 
pharmacoeconomic evaluation of variations in the following key variables: Tropisetron 
acquisition cost, AR CPM-DEX acquisition and preparation costs and patients’ 
willingness to pay per extra effectiveness unit (Table 2b). 
 
 
RESULTS AND DISCUSSION 
 
Table 3 shows TROP and CPM-DEX effectiveness, average cost and cost-effectiveness 
ratios from both analytic perspectives and for each subgroup of patients. The probability 
and the total cost associated with each of the end-points at the decision trees are 
available upon request from the authors. 
 
 
Probability calculations 
The difference in TROP effectiveness found between the two age groups (50% vs. 
33.30% and 76% vs. 57.20%, hospital’s and patients’ analytic perspectives, 
respectively) could be explained by the more complicated control of emesis in 
adolescent patients than in younger children [13]. 
 
If anxiety is the cause whereby emetic episodes and nausea are perceived as more 
frequent and acute in adolescent patients [14], its reduction as a consequence of the 
somnolence induced by CPM could explain the higher percentage of effectiveness of 
CPM-DEX in patients > 12 years of age (44.3%, hospital’s analytic perspective) with 
respect to patients ≤ 12 years of age (34.7%, hospital’s analytic perspective). 
 
The higher TROP effectiveness found in patients’ analytic perspective with respect to 
their equivalents in the hospital’s analytic perspective (76% vs. 50% and 57.20% vs. 
33.30%, 2-12 and 13-17 year-old patients’ respectively) could be explained by the 
different way in which hospital and patients evaluate TROP antiemetic response and 
tolerance. Therefore, for example, the total of the adverse effects of TROP which 
require treatment (not complying with the criteria of effectiveness from the hospital’s 
analytic perspective) are valued as tolerable by patients, fulfilling in this way the criteria 
of effectiveness from the patients’ analytic perspective. 
 
The difference of effectiveness of CPM-DEX found between the two analytic 
perspectives could be explained in 2-12 year old patients by the different way in which 
hospitals and patients evaluate CPMDEX antiemetic response and tolerance, and in 13-
17 year old patients by the intolerance which an important group of these patients shows 
towards somnolence and dizziness induced by chlorpromazine, intolerance which is not 
commonly found in very young children. 
  
 
Cost estimates 
 
The CPM-DEX/TROP average cost relation is 1:1.35 (patients’ age 2-12) and 1:1.51 
(patients’ age 13-17) from the hospital’s analytic pespective and 1:3.19 (patients’ age 2-
12) and 1:2.66 (patients’ age 13-17) from the patients’ analytic perspective. The 
difference in ratios found between the two analytic perspectives could be explained by 
the different degree of compensation of the higher acquisition cost of TROP (with 
regard to CPM-DEX). While from the patients’ analytic perspective the only 
compensating feature of the higher cost of purchase of tropisetron in the total costs are 
the associated costs of the TROP preparation, from the hospital’s analytic perspective 
this higher price is compensated for by the lower associated costs of the 
antiserotoninergic drug prescription, preparation, administration and surveillance. 
 
Analysis of the relation costs-effects 
 
The CEr T is lower than the CEr CD only in the sub-group of patients ≤ 12 years of age 
from the hospital’s analytic perspective (CEr T = $66.19 and CEr CD = $70.72). In this 
case the ratio CEr CD: CEr T is 1:0.94, thus inverting the relationship CPM-
DEX/TROP established for the average cost (1:1.35). This inversion is due to the higher 
percentage of effectiveness of TROP compared to CPM-DEX (50% vs. 34.70%) and to 
the lower percentage of failures (12.8% vs. 38.8%) that quantitatively are reducing the 
costs associated with therapeutic failure and clinical complications. 
 
The simultaneous cost-effectiveness relationship between the two alternatives is shown 
in Table 4, where the most cost-effective AR for each case is highlighted. The most 
cost-effective alternative in the subgroup of patients ≤ 12 years of age who receive 
highly emetogenic chemotherapy is the TROP from both analytic perspectives. 
 
The no coincidence of the most cost-effective alternative from both analytic 
perspectives in the subgroup of children > 12 years of age who receive highly 
emetogenic chemotherapy is resolved in favour of the option chosen from the patients’ 
analytic perspective (TROP). The previous decision takes into account not only the cost 
of the drug but also its impact on the physical, social and emotional well-being of the 
patient (ECHO model [15]). In this subgroup of patients to select CPM-DEX as the 
most favourable pharmacoeconomic alternative is unacceptable in spite of the economic 
advantages from either analytic perspectives and the advantages of effectiveness from 
the hospital’s analytic perspective, given that in 66.70% of the chemotherapy cycles in 
which it is administered the above mentioned AR is not evaluated as good by the 
patients. Other considerations which support this decision are: 
 25% of patients belonging to this subgroup of the study refuse to receive CPM-
DEX in the following chemotherapy cycle. 
 CPM-DEX has disadvantages which cannot be evaluated by patients given the 
design of the study from which the probabilities of each end-point are 
calculated. For example: 
- CPM is administered three times a day, in such a way that one or two of 
these may coincide with night-time schedules. 
- CPM tends to precipitate in alkaline solutions. When CPM is administered 
in high dosage cycles of methotrexate it is necessary, in addition to washing 
the via, to stop administering concomitant alkaline fluidotherapy for 6 hours 
with the added risk of eliminating the antimetabolite incorrectly. 
 
 
Sensitivity analysis 
 
Sensitivity analysis showed the reliability of the results: 
 The CEA are not affected by modifications in the values of the key variables 
reviewed in table 2 in the subgroup of patients ≤ 12 years of age from the 
hospital’s analytic perspective and in the subgroup of patients > 12 years of age 
from the patients’ analytic perspective. 
 In the subgroup of children ≤ 12 years from the patients’ analytic perspective the 
cost-effective subanalysis is sensitive to modifications in the key variable 
“patients’ willingness to pay per extra effectiveness unit”. When the mentioned 
variable takes on its worst theoretical value, and on the condition that the price 
of TROP does not undergo modifications with regard to its base value, CPM-
DEX will be more cost-effective than TROP. This change does not affect the 
final result of the CEA given that when faced with the results of both analytic 
perspectives TROP will still be chosen as the most cost-effective. 
 The CEA in the subgroup of patients > 12 years of age from the hospital’s 
analytic perspective is only sensitive if the values of the three key variables 
(Table 2a) are modified at the same time. In this subgroup of patients from the 
hospital’s analytic perspective TROP is more cost-effective than CPM-DEX 
only when the acquisition cost of TROP is reduced by 60% and the associated 
costs of CPM-DEX human resources take on their worst estimated value and the 
hospital is willing to pay 100% more than CEr CD per additional unit of 
effectiveness. 
 
Although the pharmacoeconomic evaluation has been carried out in the environment of 
the Department of Pediatric Oncology of the University Hospital of Navarra, the results 
are applicable to Pediatric Oncology Departments of other Spanish hospitals. First of all 
because the data of effectiveness on which the study is based can be extended to the 
whole of the pediatric oncological population which receives highly emetogenic 
chemotherapy, and secondly, because the foreseeable interhospital differences in the 
values taken on by the key cost variables do not modify the final results of the present 
study as we have proved in the sensitivity analysis. 
 
Finally, the need to increase the effectiveness of tropisetron with strategies such as the 
addition of a corticoid should be noted, given that in pediatric patients who receive 
highly emetogenic chemotherapy with an antiemetic regimen based only on TROP the 
percentage of effectiveness does not surpass the 50%. 
 
 
 
CONCLUSIONS 
 
 TROP was more cost-effective than CPM-DEX in the control of acute 
emesis induced by highly emetogenic chemotherapy in children. 
 When antiemetics are evaluated pharmacoeconomically it is important to 
take into account the patients’ analytic perspective in addition to the 
hospital’s analytic perspective, as it is possible in this way to avoid 
giving more importance to the cost of the drug compared to the relevance 
of its impact on the physical, social and emotional well-being of the 
patient. 
 It seems necessary to increase the effectiveness of TROP in pediatric 
patients receiving highly emetogenic chemotherapy with strategies such 
as the addition of a steroid. 
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Figure 1. Decision tree, hospital’s analytic perspective 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Decision tree, patients’ analytic perspective 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Graph representing the function of the theoretical model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
